Study of TBI-1301 (NY-ESO-1 Specific TCR Gene Transduced Autologous T Lymphocytes) in Patients With Solid Tumors

Lung Cancer Clinical Trial

Official title:

Phase Ib Study of TBI-1301 (NY-ESO-1 Specific TCR Gene Transduced Autologous T Lymphocytes) in Patients With Solid Tumors

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT02869217
• Other study ID #: 1301-02
• Status: Active, not recruiting
• Phase: Phase 1
• Start date: September 2016
• Est. completion date: September 2024

Study information

• Verified date: December 2023
• Source: University Health Network, Toronto
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The target populations for this phase I study with TBI-1301 are patients with advanced solid tumors. Patients' tumors will be required to express NY-ESO-1, which include but is not limited to ovarian cancer, synovial sarcoma, esophageal cancer, lung cancer, bladder cancer, liver cancer, and malignant melanoma. Patients must be positive for HLA-A*02:01 or HLA-A*02:06 and the patient's tumor tissue must be positive for NY-ESO-1 antigen expression. The study will take the subject's T cells, which are a natural type of immune cell in the blood, and send them to a laboratory to be modified. The changed T cells used in this study will be the subject's own T cells that have been genetically changed with the aim of attacking and destroying cancer cells. The manufacturing of T cells takes about 1 month to complete. The T cells will be given back to the subject through an intravenous infusion. The purpose of this study is to test the safety of genetically changed T cells and find out what effects, if any, they have in subjects with advanced solid tumors. The purpose of this study is to evaluate the safety profile of TBI-1301, to determine the recommended phase 2 (RP2D) dose of TBI-1301 when administered following cyclophosphamide and fludarabine pre-treatment, to evaluate the safety of repeat dosing of TBI-1301, to assess the presence/absence of RCR appearance after TBI-1301 infusion, to assess the presence or absence of clonality by LAM-PCR, and to evaluate evidence of efficacy of TBI-1301 using RECIST v1.1.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 22
• Est. completion date: September 2024
• Est. primary completion date: September 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 16 Years and older

Eligibility

Inclusion Criteria:

• Histologically or cytologically confirmed metastatic or recurrent unresectable solid tumor.
• HLA-A*02:01 or HLA-A*02:06 positive.
• Tumor NY-ESO-1 expression by immunohistochemistry.
• No anti-cancer chemotherapy, radiation therapy or immunotherapy within 2 weeks or 5 half-lives of PBMC harvest.
• The treating investigator should consider the patient to have disease that is incurable and that the patient would be a reasonable candidate for future treatment with TBI-1301.
• Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded for non-nodal lesions and short axis for nodal lesions) as >10 mm with CT scan, MRI, or calipers by clinical exam. Patients must have radiographic evidence of disease progression following the most recent line of treatment. Areas of previous radiation may not serve as measurable disease unless there is evidence of progression post radiation.
• ECOG Performance Status 0 or 1.
• Age =16 years on consent.
• Life expectancy greater than 4 months.
• The following laboratory requirements must be met (within 14 days prior to phlebotomy

for generation of TBI-1301):

• Absolute neutrophil count (ANC) =1.5 x10^9/L (1500/µL) without G-CSF support
• WBC = 2.5x10^9/L (2,500/µl)
• Lymphocytes = 0.5x10^9/L (500/µl)
• Hemoglobin = 80 g/L
• Platelets = 75x10^9/L (75,000/µl)
• Total bilirubin = 1.5 x upper limit of normal (ULN) (=2.5X if Gilbert's disease)
• AST(SGOT), ALT(SGPT) < 3.0 x ULN (< 5 x ULN with known liver metastases)
• Creatinine = 60 ml/min (calculated by Cockcroft and Gault)
• Adequate renal function
• Consent must be appropriately obtained in accordance with applicable local and regulatory requirements.

Exclusion Criteria:

• Uncontrolled intercurrent illnesses or medical conditions that may interfere with trial participation such as ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, cardiac arrhythmia, severe active peptic ulcer disease or gastritis, or psychiatric illness/social situations that would limit compliance with study requirement or compromise the ability of the subject to give written informed consent.
• Patients who are receiving any other investigational agents.
• Active or prior documented autoimmune disease within the past 2 years. NOTE: Subjects with vitiligo, Grave's disease, Hashimoto's disease, or psoriasis not requiring systemic treatment (within the past 2 years) are not excluded.
• Active or prior documented inflammatory bowel disease (eg, Crohn's disease, ulcerative colitis).
• No evidence of active uncontrolled infection (patients on antibiotics are eligible).
• History of primary immunodeficiency.
• History of organ transplant that requires use of immunosuppressives.
• Known allergy or reaction to a known component of TBI-1301.
• Untreated central nervous system metastases requiring concurrent treatment, inclusive of but not limited to surgery, radiation, and/or corticosteroids. If treated lesions are shown to be stable for 1 month the subject may be eligible.
• Other invasive malignancy within 2 years except for noninvasive malignancies such as cervical carcinoma in situ, non-melanomatous carcinoma of the skin or ductal carcinoma in situ of the breast that has/have been surgically cured.
• Current or prior use of immunosuppressive medication within 14 days before phlebotomy, with the exceptions of intranasal, topical, and inhaled corticosteroids or systemic corticosteroids at physiologic doses not to exceed 10 mg/day of prednisone or equivalent. Oral steroid use as premedication to prevent allergic reactions to radiologic contrast is allowed.
• Any condition that, in the opinion of the investigator, would interfere with the evaluation of TBI-1301 or interpretation of subject safety or study results.
• Known history of tuberculosis.
• HIV positive.
• Active HTLV or syphilis infection.
• Active hepatitis B infection (hepatitis B surface antigen or HBV DNA positive).
• Active hepatitis C infection (if hepatitis C antibody positive, HCV RNA positive).
• Has no known active central nervous system metastases and/or carcinomatous meningitis.
• Ongoing prior toxicities related to previous anti-cancer treatments (surgery, radiotherapy or adjuvant chemo-radiation) must be recovered to < grade 1 or baseline
• Pregnant women are excluded.

Related Conditions & MeSH terms

• Bladder Cancer
• Esophageal Cancer
• Liver Cancer
• Lung Cancer
• Melanoma
• NY-ESO-1 Expressing Solid Tumors in HLA-A2 Positive Patients
• Ovarian Cancer
• Sarcoma, Synovial
• Synovial Sarcoma

Intervention

Drug:
• Cyclophosphamide

Biological:
• TBI-1301

Drug:
• Fludarabine

Locations

Country	Name	City	State
Canada	Princess Margaret Cancer Centre	Toronto	Ontario

Sponsors (2)

Lead Sponsor	Collaborator
University Health Network, Toronto	Takara Bio Inc.

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Safety profile (i.e. adverse events, presence/absence of RCR, analysis of clonality and PK of TBI-1301) assessed by CTCAE v.4.0 and laboratory testings.		8 weeks
Primary	Recommended phase 2 (RP2D) dose o TBI-1301 when administered following cyclophosphamide and fludarabine pre-treatment		8 weeks
Secondary	Evidence of efficacy (i.e. anti-tumor effect) of TBI-1301 measured using RECIST v1.1		8 weeks